omniture

China Sky One Medical Announces Health Food Product Pipeline

2011-01-11 21:08 1645

HARBIN, China, Jan. 11, 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced that following the Tang Wang He forest land acquisition, the Company plans to develop, manufacture and market thirteen new health food products, including teas, oral liquids and herbal wines. These products are expected to receive approvals from China's State Food and Drug Administration ("SFDA") in 2011. The Company will leverage its existing sales network to sell the following new products to consumers through pharmacies:

Category

 

Name

 

Utility

 

Expected SFDA Approval

 
 

Health Tea

 

Tea from Acanthopanax Root

 

To nourish blood, improve appetite and facilitate sleep

 

Q2 2011

 
 

Tea from Fruit of Chinese Magnoliavine

 

To energize, improve memory and combat fatigue

 

Q2 2011

 
 

Tea from Pinus Prokoraiensis Needles

 

Antioxidant, anti-aging

 

Q2 2011

 
 

American Ginseng Tea

 

To adjust endocrine and enhance immunity

 

Q2 2011

 
 

Astragalus Mongholicus Ginseng Tea

 

To energize and improve cardiac muscle strength

 

Q2 2011

 
 

Health Oral Liquid

 

Blueberry Oral Liquid

 

Antioxidant, anti-aging

 

Q3 2011

 
 

Honeysuckle Oral Liquid

 

Anti-virus, to improve immunity

 

Q3 2011

 
 

Rose Hip Oral Liquid

 

To supplement Vitamin C, antioxidant

 

Q3 2011

 
 

Pinus Prokoraiensis Needles Oral Liquid

 

Antioxidant, anti-aging

 

Q3 2011

 
 

Health Herbal Wine

 

Kidney Invigorating Wine

 

To invigorate the kidney  

 

Q1 2011

 
 

Longevity Wine

 

To energize and rejuvenate

 

Q1 2011

 
 

Rheumatism Wine

 

To activate blood circulation; to dissipate blood stasis and rheumatism

 

Q1 2011

 
 

Nerve relieving Wine

 

To nourish blood and for tranquilization

 

Q1 2011

 
 
       

The Company also reached an agreement with the research division of Heilongjiang Traditional Chinese Medicine University, which will transfer the ownership of eleven patch products at fair market value prices to the Company upon receipt of corresponding production approvals. These products include: Breast and Uterus Patch, Heart Patch, Headache Patch, Intestines Patch, Bowel Relaxing Patch, Onychomycosis Patch, Dry Skin Patch, Cold and Fever Patch, Carsickness Patch, Bone Healing Patch, and Waist Patch.

"We look forward to the commercial launch of these new health food and patch products and expect to continue to diversify our rich product portfolio to strengthen the Company's competitive position and support sustainable long-term growth," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "We are now working on the sales forecast for these new products and will update investors with the 2011 full year financial forecast soon."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, Heilongjiang Tianlong Pharmaceutical, Inc. and Peng Lai Jin Chuang Pharmaceutical Company, the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn.

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the Company's development of product pipeline. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

Investor Relations Contact: 

China Sky One Medical               CCG Investor Relations 
Yanqing Liu, CEO                    Crocker Coulson, President 
 Email: ir@cski.com.cn              Tel: +1-646-213-1915 
                                    Email: crocker.coulson@ccgir.com  
                                    Website: www.ccgirasia.com 

                                    Mabel Zhang, Vice President 
                                    Tel: +1-310-954-1353 
                                    Email: mabel.zhang@ccgir.com
Source: China Sky One Medical, Inc.
Related Stocks:
NASDAQ:CSKI
collection